Mayo Clinic Forms Joint Venture With Cancer Genetics
Mayo Clinic ("Mayo") and Cancer Genetics Inc. recently launched OncoSpire Genomics ("OncoSpire"), a joint venture with the singular goal of improving cancer care by discovering and commercializing diagnostic tests that leverage next-generation sequencing.
Liquidia Technologies Announces Extension Of Collaboration With PATH To Develop Next Generation Pneumococcal Vaccine
Liquidia Technologies recently announced that its collaborative agreement with PATH, a global health nonprofit organization, has been extended.
Transgene Announces Its Invesment In ElsaLys Biotech, A New Antibody Company Created By Former Executives
Regulatory News: Transgene SA , a biopharmaceutical company that develops targeted immunotherapy products to treat major unmet medical needs in cancer and chronic infectious diseases, recently announced its participation to the first private equity round of Elsalys Biotech, a newly created therapeutic monoclonal antibody player.
The Start-Up Elsalys Biotech, A New Player In The Therapeutic Monoclonal Antibody Arena, Announces The First Round Of Financing With Transgene And Sofimac Partners
ElsaLys Biotech, which specializes in the development of therapeutic monoclonal antibodies, announces a first round of financing of 2.1M€ from the biopharmaceutical company Transgene and the investment fund Sofimac Partners.
Otsuka's New Drug Application For Tolvaptan, The Investigational Compound For Autosomal Dominant Polycystic Kidney Disease (ADPKD), Accepted for Review By The US Food And Drug Administration (FDA)
Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has accepted for priority review the company's new drug application (NDA) for the potential use of tolvaptan for the treatment of autosomal dominant polycystic kidney disease (ADPKD).
Emergent BioSolutions Presents Efficacy Data On ES210; A Bispecific ADAPTIR Molecule For Treating Autoimmune Diseases
Emergent BioSolutions Inc. (NYSE: EBS) announced today that it has presented data on ES210, one of its bispecific ADAPTIRTM (Modular Protein Technology) molecules, that is targeting autoimmune disease at Keystone Symposia’s Advances in the Knowledge and Treatment of Autoimmunity in Whistler, British Columbia, Canada.
2013 BIO International Convention To Host Alzheimer’s Forum
According to the Alzheimer’s Association, in 2013, the disease will cost the nation $203 billion and this number is expected to rise to $1.2 trillion by 2050.
PeptiDream And Ipsen Enter Into A Collaboration For Advancing Drug Discovery Efforts For Peptides To Treat Serious Disease
Regulatory News: PeptiDream Inc., a Tokyo-based pharmaceutical company (PeptiDream), and Ipsen (Euronext: IPN, ADR: IPSEY), a global specialty driven pharmaceutical Group, recently announced that they have entered into a research collaboration and license option agreement to discover, evaluate, potentially develop and launch therapeutic peptides to treat serious medical conditions in areas of therapeutic focus for Ipsen.
BioLineRx Receives Regulatory Approval To Commence Phase II Clinical Trial For BL-8040, For Treatment Of Leukemia
BioLineRx, a biopharmaceutical development company, announced recently that it has received all necessary regulatory approvals in the US to commence a Phase IIa trial for BL-8040, for the treatment of Acute Myeloid Leukemia (AML).
InVivo Therapeutics Receives Approval From FDA For First Human Trial Using Biomaterials For Traumatic Spinal Cord Injury
InVivo Therapeutics Holdings Corp. (NVIV), a developer of groundbreaking technologies for the treatment of spinal cord injuries (SCI) and other neurotrauma conditions, recently announced that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational Device Exemption (IDE) to begin human studies to test its biopolymer scaffold product, a technology developed to treat patients with acute, traumatic SCI.